Journal · Bone Health · Updated 15 November 2026
Osteoporosis International
Read Osteoporosis International research on DeepDyve. No university library needed.
Osteoporosis International, published by Springer Nature, has covered research on osteoporosis and other bone diseases since 1990. Its papers look at how to diagnose, prevent and treat bone loss and fractures, including studies of drugs such as teriparatide, denosumab and bisphosphonates and of exercise. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Osteoporosis International at a glance
- Full title
- Osteoporosis International
- Abbreviation (NLM)
- Osteoporos Int
- Publisher
- Springer Nature
- Print ISSN
- 0937-941X
- Online ISSN (eISSN)
- 1433-2965
- First published
- 1990
- Subjects
- Metabolism, Orthopedics
- Access model
- Hybrid: subscription, with an open access option
- On DeepDyve
- Research articles; availability varies by article
Ways to access Osteoporosis International
32% of the articles Osteoporosis International published from January 1 to November 14, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 32% of Osteoporosis International articles published from January 1 to November 14, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Osteoporosis International. Check its journal list and whether it offers remote access.
- DeepDyve. Read Osteoporosis International articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Recent Osteoporosis International research worth reading
Published May to August 2026. Summaries describe what the authors report.
-
Acute immune-mediated hepatocellular injury temporally associated with romosozumab: a probable autoimmune-like drug-induced liver injury
The authors report a 72-year-old woman whose liver enzymes rose to more than 20 times the upper limit of normal after three monthly doses of romosozumab, an injury they rate as probably drug-related and which resolved only after prolonged corticosteroid treatment.
de Andrade et al. · Osteoporosis International, published online May 8, 2026 · DOI 10.1007/s00198-026-07988-6
-
Pre-teriparatide anti-osteoporosis medication therapy and fracture-related hospitalization in patients at very high fracture risk
In a Taiwanese cohort of 14,770 patients at very high fracture risk who started teriparatide, the authors report that earlier osteoporosis medication did not raise fracture-related hospitalization overall, but 3 or more years of denosumab was linked to more spine fracture hospitalizations (adjusted hazard ratio 1.86).
Fu et al. · Osteoporosis International, published online June 2, 2026 · DOI 10.1007/s00198-026-08081-8
-
Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates
In a 2-year randomized trial of 44 postmenopausal women stopping long-term denosumab, the authors report that most of those with no earlier bisphosphonate use needed multiple zoledronate infusions (median 2), while most previously exposed to bisphosphonates needed only one.
Ferrari et al. · Osteoporosis International, published online June 29, 2026 · DOI 10.1007/s00198-026-08115-1
-
Influence of bisphosphonate pretreatment on bone mineral density gains and fracture outcomes with teriparatide: A systematic review and meta-analysis
Pooling 15 studies of 8,763 bisphosphonate-pretreated and 7,071 untreated individuals, the authors report that earlier bisphosphonate use was linked to a smaller lumbar spine bone density gain with teriparatide (mean difference of 2.21 percentage points), with no significant difference at the hip or femoral neck.
Osteoporosis International, July 2026 · DOI 10.1007/s00198-026-08136-w
-
Effects of weighted vest on bone health and body fat in middle-aged and older adults: a systematic review and meta-analysis
Pooling nine randomized trials with 368 middle-aged and older adults, the authors report that wearing a weighted vest during exercise improved femoral neck and lumbar spine bone density and cut body fat by 2.67 kg compared with usual activity, but added no significant bone benefit over exercise alone.
Wang et al. · Osteoporosis International, published online August 14, 2026 · DOI 10.1007/s00198-026-08196-y
Related journals
Questions about Osteoporosis International
How can I read Osteoporosis International articles without a subscription?
32% of Osteoporosis International articles published from January 1 to November 14, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Osteoporosis International articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Osteoporosis International?
Osteoporosis International’s NLM (PubMed) abbreviation is Osteoporos Int.
What is the ISSN of Osteoporosis International?
The print ISSN is 0937-941X and the online ISSN is 1433-2965.
Is Osteoporosis International open access?
Osteoporosis International is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 14, 2026, 103 of 317 Osteoporosis International articles (32%) carry a Creative Commons license, per Crossref.
Osteoporosis International articles on DeepDyve are licensed from Springer Nature. Journal facts as of 15 November 2026.
Start reading Osteoporosis International today
One month free, then less than $2 a day. Osteoporosis International, plus millions of articles from thousands of journals.




